Stryker announced it has acquired Molli Surgical and its miniature tissue marker for targeting breast cancer lesions during surgery.

After more than two decades of work on neurodegenerative diseases, Swiss biotech AC Immune claims it could have a game changer on its hands.

GSK has scrapped a phase 2 human papillomavirus (HPV) vaccine from its pipeline after deciding the asset wouldn’t have best-in-class potential.

Digital technology company inFormed Consent has partnered with healthcare business development firm trifermed to launch a platform that will allow researchers to obtain informed consent from clinical trial participants remotely.

As brain-computer interface developer Synchron has tried to expand how its tech links with the brain, it’s now trying to do the same with the computers. The company has reported that one of its implanted patients was able to control an Apple Vision Pro headset for the first time.

An old GLP-1 that has since been outshined by Ozempic may have a new path to the limelight. In a small phase 2 trial of patients with mild Alzheimer’s disease, Novo Nordisk’s liraglutide slashed cognitive decline by 18%.

For the second quarter in a row, Incyte has used its earnings results to significantly slim down its early-stage pipeline as the Jakafi-maker channels its resources toward “high potential impact programs.”

It’s not easy to muscle in on a space as competitive as immunology, but Celldex Therapeutics believes that its latest phase 2 win in a chronic form of hives means it has a shot at carving out its own niche.

Toxoplasma gondii is a protozoan parasite famous for its cunning ways. This microbial manipulator can only reproduce inside of cats, so, if it finds itself in another mammalian host, like a rat, it alters the rodent’s behavior to make it less fearful of felines. This effect has even been found in wild spotted hyena cubs, who behave more boldly toward lions when infected with T. gondii.

Guardant Health aims to reshape how the U.S. gets screened for colorectal cancer, by claiming a groundbreaking FDA approval for a tumor-detecting blood test aimed at a population of about 120 million people.